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Background: Epigenome-wide studies in hepatocellular carcinoma (HCC) have identified numerous genes with
aberrant DNA methylation. However, methods for triaging functional candidate genes as useful biomarkers for
epidemiological study have not yet been developed.
Methods: We conducted targeted next-generation bisulfite sequencing (bis-seq) to investigate associations of DNA
methylation and mRNA expression in HCC. Integrative analyses of epigenetic profiles with DNA copy number
analysis were used to pinpoint functional genes regulated mainly by altered DNA methylation.
Results: Significant differences between HCC tumor and adjacent non-tumor tissue were observed for 28 bis-seq
amplicons, with methylation differences varying from 12% to 43%. Available mRNA expression data in Oncomine were
evaluated. Two candidate genes (GRASP and TSPYL5) were significantly under-expressed in HCC tumors in comparison with
precursor and normal liver tissues. The expression levels in tumor tissues were, respectively, 1.828 and − 0.148, significantly
lower than those in both precursor and normal liver tissue. Validations in an additional 42 paired tissues showed consistent
under-expression in tumor tissue for GRASP (−7.49) and TSPYL5 (−9.71). A highly consistent DNA hypermethylation and
mRNA repression pattern was obtained for both GRASP (69%) and TSPYL5 (73%), suggesting that their biological function is
regulated by DNA methylation. Another two genes (RGS17 and NR2E1) at Chr6q showed significantly decreased DNA
methylation in tumors with loss of DNA copy number compared to those without, suggesting alternative roles of DNA
copy number losses and hypermethylation in the regulation of RGS17 and NR2E1.
Conclusions: These results suggest that integrative analyses of epigenomic and genomic data provide an efficient way to
filter functional biomarkers for future epidemiological studies in human cancers.Background
Epigenome-wide association studies [1–7], including ours
[8, 9] have identified large panels of genes with aberrant
DNA methylation in hepatocellular carcinoma (HCC). In
two previous studies, we found an overlap of 402 signifi-
cantly hypermethylated and 985 hypomethylated genes in
HCC tumor tissues in comparison with adjacent non-
tumors using Illumina 27K and 450K methylation arrays
[8, 9]. Hypermethylation of 275 of the genes was consist-
ent with other epigenome-wide studies [1–7], and the
gene list includes several well-known tumor suppressor
genes (TSGs) such as APC (adenomatous polyposis coli),
p16/CDKN2A (cyclin-dependent kinase inhibitor 2A) and
RASSF1 (Ras association domain family member 1). These* Correspondence: js2182@cumc.columbia.edu
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results. Simultaneously, a large number of genes were
identified for the first time as aberrantly methylated (127
hypermethylated and 308 hypomethylated) in HCC tumor
tissue [8, 9] providing a resource to examine novel etio-
logical risk factors and biologically relevant epigenetic
markers for early diagnosis of HCC. Whether the aberrant
methylation has functional consequences and can serve as
sensitive markers of HCC is largely unknown in population-
based epidemiological studies. Moreover, there is a lack of
systematic analyses that integrate DNA methylation changes
with genetic/epigenetic factors (copy number variations
(CNVs), microRNA (miRNA) expression and histone modi-
fication, etc.) that potentially influence a gene’s biological
functions. From the viewpoint of epidemiological studies
alone, evidence of significant differences in DNA methyla-
tion between tumor and non-tumor tissues is insufficient to
establish a causative role for the candidate genes incle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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vious epigenome-wide association studies [1–9] has compli-
cated their application in larger population-based validation
studies to determine in a cost-effective way their utility as
risk factors, as well as early diagnostic/prognostic markers.
Therefore, comprehensive analyses of available genetic and
epigenetic data together may help us to better understand
the functions of genes identified as being mainly regulated
by aberrant DNA methylation, and narrow down the num-
ber of crucial methylation markers involved in hepatocarci-
nogenesis for future large epidemiological studies, including
those which might involve using blood as an indirect surro-
gate, or cell-free tumor-derived DNA as a directly relevant
analyte.
A limited number of CpG sites per gene or region are
analyzed in genome-wide array-based methylation studies.
Thus, we conducted further analysis by targeted next-
generation bisulfite sequencing (bis-seq) to validate the
genes identified as having the largest changes in DNA
methylation based on both Illumina 27K and 450K array
data. Our targeted bis-seq approach used PCR based amp-
lification followed by sequencing on an Illumina MiSeq to
cover multiple CpG sites (2–57 CpG sites) in candidate
genes. This method allows for nucleotide level resolution
and high sequencing depth and was able to cover multiple
CpG sites for each of the candidate genes. To further in-
vestigate genes of interest and identify genes with inverse
associations between DNA methylation and expression,
we integrated the DNA methylation data with a genomic
database of mRNA expression in HCC tissues and other
cancer tissues, as well as cancer cell lines. Finally, we fur-
ther examined the influence of genetic/epigenetic factors
(such as CNVs, miRNA expression, histone modifications,
etc) on gene expression to distinguish functional candi-
dates mainly regulated by DNA methylation that may
serve as promising early diagnostic markers.
Methods
Study subjects
This study was approved by the Institutional Review
Board of Columbia University Medical Center. ). A waiver
of consent was given because the majority of patients died
before the research was carried out. Some of the living pa-
tients did give informed consent due to their interests in
participating in further follow-up study. Sixty-six frozen
HCC tissues from the Molecular Pathology Shared Re-
source of the Herbert Irving Comprehensive Cancer Cen-
ter, as well as their detailed histological and clinical
features including HBV (HBsAg) and HCV (anti-HCV)
status were available from our prior study of methylation
using Illumina arrays [9]. Twenty-four of these paired
tumor/adjacent non-tumor tissues with different viral sta-
tus were selected for targeted bis-seq of multiple CpG
sites to determine methylation level, as well as for mRNAexpression measured by quantitative reverse transcription
PCR (qRT-PCR).
Selection of candidate genes and regions
To select candidate genes and regions for further valid-
ation of DNA methylation by targeted bis-seq, we com-
pared the significant CpG sites and genes identified in
our previous studies using Illumina 450K and 27K arrays
that were deposited in NCBI’s Gene Expression Omni-
bus (GEO) database (accession number GSE54751 and
GSE37988) [8, 9]. We found an overlap of 402 hyper-
methylated genes (covering 505 CpG sites) and 985
hypomethylated genes (covering 1242 CpG sites). Be-
cause previous studies using a candidate gene approach
have found more hypermethylated TSGs and DNA re-
pair genes [10–21] than hypomethylated oncogenes in
HCC, we selected a total of 20 hypermethylated and
eight hypomethylated genes for the current study. Each
gene had a >20% DNA methylation difference between
HCC tumor and non-tumor tissues and a Bonferroni ad-
justed p value <0.05. For each hypermethylated gene, at
least two amplicons were designed to cover candidate
CpG sites, and one amplicon was designed for hypo-
methylated genes. Finally, a total of 48 PCR primers
pairs were used, and after sequencing, low quality se-
quences were removed and genome alignment carried
out. Twenty-nine of the amplicons covering 20 genes
were successful and analyzed in the current study.
Laboratory methods
Bisulfite treatment was performed on 1μg DNA using
the Epitect kit (Qiagen) as per the instructions. The
genomic locations of candidate genes and covered CpG
sites of the amplicons for targeted bis-seq are given in
Additional file 1: Table S1. Oligonucleotide primers
were designed around the CpGs of interest using
MethPrimer (http://www.urogene.org/cgi-bin/methpri-
mer/methprimer.cgi) [22], and the CS1 and CS2 Flui-
digm tags were added. Primers were synthesized
(IDTDNA) and verification of the amplicon size was
performed. The Fluidigm Access Array was performed
with the KAPA HiFi 2x Uracil + polymerase. Next the
adapter and barcode sequences were added following
the Fluidigm protocol using the Faststart Hi Fidelity kit
(Roche) and the barcoded primers (Fluidigm). Verifica-
tion of product was done on an agarose gel and
cleaned-up using the Agencourt AMPure XP (Beckman
Coulter). Libraries were then quantified using the Kapa
Library Quantification Kit (Kapabiosystems). Samples
were then pooled with 30–50% PhiX (Illumina) and
loaded onto the MiSeq (Illumina) for sequencing. Li-
braries are clustered and sequenced with 250 nucleotide
paired-ends. The Fastq files generated by sequencing
were trimmed for both adapters and for a quality cut off
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raham.ac.uk/projects/trim_galore/). Sequencing alignment
and methylation calls were done via Bismark [23] and
bowtie2 [24]. The genome used for alignment was recent
human assembly GRCh37/hg19.
Total RNA, including miRNA was isolated from frozen
HCC tumor and adjacent non-tumor tissues by Qiazol and
RNeasy Microarray Tissue Mini Kits (Qiagen) according to
the manufacturer’s protocol. For mRNA expression, 1.0 μg
isolated RNA (10μL) was converted to cDNA using the
High-Capacity cDNA Reverse Transcription Kit. After 10
times dilution of the RT products, TaqMan® Gene Expres-
sion Assays (Life Technologies) were used to detect two
candidate genes GRASP (general receptor for phosphoino-
sitides 1-associated scaffold protein: Hs00699132_g1) and
TSPYL5 (TSPY-like 5: Hs00603217_s1). Data were normal-
ized by the housekeeping gene GAPDH (glyceraldehyde-3-
phosphate dehydrogenase: Hs02758991_g1) as recom-
mended by a study to validate putative reference genes in
HCC tissues [25]. TaqMan Low Density Arrays (TLDA,
Life Technologies), covering 670 unique human mature
miRNAs were used to generate genome-wide miRNA pro-
files that was deposited in NCBI’s GEO database (accession
number GSE54751) [26].
Integrative analyses
The Oncomine database (https://www.oncomine.org)
[27, 28] that includes cancer microarray data deposited
in GEO and the Stanford Microarray Database (SMD)
were used to determine the differences in mRNA ex-
pression between HCC tumor and/or precursor/normal
liver tissues for 20 candidate genes, as well as the well-
known TSGs APC, CDKN2A and RASSF1 [8, 9]. Fifteen
publicly available datasets were selected for the integra-
tive analyses (http://tcga-data.nci.nih.gov/tcga/) [29–42].
Details of standardized normalization techniques and
statistical methods can be found on the Oncomine web-
site [27, 28]. The gene expression data were log2 trans-
formed, median centered per array, and the standard
deviation (SD) was normalized to one per array [27, 28].
Genes with significant differences in mRNA expression
(p ≤ 0.05) and a concordant DNA methylation and mRNA
expression pattern (i.e. hypermethylation with under-
expression or hypomethylation with up-regulation) in liver
tissues were further examined for the potential impacts of
CNVs (gain or loss) using both Oncomine and our 450K
methylation intensity data by DNA-Chip Analyzer (dChip)
[43]. Others were excluded from further analysis. The ex-
pression levels of miRNAs (increase or decrease) that target
hypermethylated genes without losses of CNVs were ana-
lyzed. The target genes of miRNAs were identified from an
online resource (http://c1.accurascience.com/miRecords/).
Finally, Encyclopedia of DNA Elements (ENCODE) data
(https://genome.ucsc.edu/ ENCODE/) for an HCC cellline (HepG2) and another seven cancer cell lines
(GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK and
NHLF) were incorporated with DNA methylation results
from candidate genes to examine the co-operative role of
histone modifications and deoxyribonuclease (DNase I)
hypersensitivity on chromatin activity. Studies showed that
active histone marks include histone 3 lysine 4 monomethy-
lation (H3K4me1) typically associated with transcriptional
enhancers; histone 3 lysine 4 trimethylation (H3K4me3) typ-
ically associated with promoters; and histone 3 lysine 27
acetylation (H3K27ac) typically associated with both active
promoters and enhancers [44, 45]. Histone 3 lysine 27 tri-
methylation (H3K27me3) acts as a repressive histone
marker to epigenetically control gene transcription [46].
DNase I sensitivity is an indicator of open chromatin, and
DNase I hypersensitivity sites are typical marks for active
regulatory regions [47].
Statistical analysis
Paired t-tests with Bonferroni correction for multiple testing
were used to compare differentially methylated genes be-
tween tumor and adjacent non-tumor tissues. A significant
difference was defined as an amplicon with a Bonferroni-
corrected p-value ≤ 0.05. Hierarchical clustering of data was
performed with the significant amplicons by tissue status
(tumor vs. adjacent non-tumor). Each gene or miRNA’s ex-
pression was separately assessed for tissue differences by
one-sided Student’s t test (under-expression for hypermethy-
lated genes or over-expression for hypomethylated genes).
Pearson’s correlation was used to analyze the relationship
between DNA methylation and mRNA/miRNA expression.
Chi-square test was used to analyze the impacts of CNVs
(gain, no change and loss) on gene expression (under- or
up-regulation). Statistical analyses were conducted using
Statistical Analysis System 9.0 (SAS Institute).
Results and discussion
Clinical and pathological characteristics of HCC patients
Clinical and pathological characteristics are described in
Additional file 1: Table S2. The average age at HCC diag-
nosis is 57.1 ± 7.5 years. More patients are male (83%),
Caucasian (54%) and positive for either HBV (33.3%) or
HCV (33.3%) or both (16.7%). The same proportion
(45.8%) is ever smokers or alcohol drinkers. Among HCC
patients, 87.5% have pathologically defined cirrhosis and
62.5% have tumors grade III or IV.
Comparison of DNA methylation results from targeted
bis-seq and Illumina arrays
A total of 29 CpG amplicons covering 20 genes (15
hyper- and 5 hypo-methylated genes) were sequenced by
targeted bis-seq. The average covered CpG sites for each
gene was 22, and ranged from 2 to 57 (Table 1). Statisti-
cally significant methylation differences between tumor








Non-tumor Tumor Difference Adjusted
P value *Mean, SD Mean, SD
CDKL2 CDKL2.a 11 6.49 (8.35) 33.52 (18.80) 27.03 2.50E-04
CDKL2 CDKL2.b 15 7.59 (11.57) 41.29 (21.98) 33.70 1.94E-04
CDKL2 CDKL2.c 27 13.20 (13.50) 37.15 (20.68) 23.95 2.83E-02
CLCN1 CLCN1 28 16.31 (10.83) 47.84 (21.93) 31.53 3.01E-04
DUOX1 DUOX1 36 16.93 (16.93) 36.98 (24.43) 20.05 2.77E-01
GRASP GRASP.a 24 12.66 (8.70) 42.45 (23.56) 29.79 3.92E-04
ILDR2 ILDR2.a 23 7.66 (4.22) 43.18 (27.32) 35.52 4.21E-05
MAST1 MAST1.a 16 16.40 (20.56) 59.15 (33.23) 42.75 4.99E-04
MAST1 MAST1.b 2 10.42 (10.98) 34.74 (21.02) 24.32 4.33E-03
MAST1 MAST1.c 19 15.25 (8.44) 38.92 (14.03) 23.67 5.15E-05
NKX6-2 NKX6-2.b 24 26.17 (9.56) 54.97 (17.70) 28.80 4.25E-05
OTX1 OTX1.a 8 22.53 (9.14) 52.15 (24.09) 29.62 2.63E-03
OTX1 OTX1.b 28 17.68 (12.10) 49.60 (17.44) 31.92 1.85E-04
SERHL SERHL.a 16 11.94 (4.38) 35.71 (13.19) 23.77 3.82E-07
SERHL SERHL.b 11 4.86 (2.26) 17.15 (12.24) 12.29 1.08E-03
SPAG6 SPAG6.b 53 16.07 (5.05) 34.12 (15.67) 18.04 1.59E-03
SPDYA SPDYA.b 11 46.93 (17.40) 73.91 (18.14) 26.98 1.29E-02
TRIL TRIL.a 16 18.13 (6.02) 53.25 (20.58) 35.12 1.01E-05
TRIL TRIL.b 22 13.88 (8.85) 36.95 (17.75) 23.07 2.22E-03
TRIL TRIL.c 17 9.73 (6.70) 41.44 (17.52) 31.71 6.62E-06
TRIL TRIL.e 44 12.10 (10.22) 38.52 (19.07) 26.42 1.55E-03
TSPYL5 TSPYL5 57 13.83 (12.12) 41.21 (18.79) 27.38 8.09E-04
USP44 USP44.c 9 61.31 (10.17) 73.45 (10.01) 12.14 6.81E-03
ZNF397OS ZNF397OS.a 32 13.76 (11.59) 38.94 (18.21) 25.18 3.10E-04
FAM66B FAM66B 13 91.18 (3.59) 71.89 (17.30) −19.29 9.49E-04
KCNQ2 KCNQ2 44 74.06 (14.65) 45.21 (22.68) −28.85 3.99E-03
PROKR2 PROKR2 14 83.57 (14.68) 65.11 (12.97) −18.46 1.11E-02
PTPRN2 PTPRN2 8 74.68 (11.71) 53.60 (17.39) −21.08 6.50E-03
REXO1L2P REXO1L2P 12 84.14 (14.58) 53.98 (22.99) −30.16 1.75E-03
* All adjusted p values are less than 0.05 with Bonferroni correction for multiple testing except DUOX1
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were observed for 28 amplicons with methylation differ-
ences varying from 12% to 43%, including 14 hyper- and 5
hypo-methylated genes. Only one hypermethylated gene
(DUOX1) showed a non-significant tumor/non-tumor dif-
ference (p = 0.277). This suggests that about 5% (1/20) of
genes identified by Illumina 450K array may be false posi-
tive findings even after adjustment for multiple compari-
son and using stringent selection criteria.
The results of targeted bis-seq are shown for GRASP
(25 CpG sites) and TSPYL5 (57 CpG sites) in Additional
file S1: Figure S1. Generally, within each sample, DNA
methylation levels across different CpG sites were consist-
ent regardless of tumor status. For hypermethylated genes,most tumor tissues displayed higher levels of DNA methy-
lation compared to adjacent non-tumor tissues for each
individual CpG site and the mean of all CpG sites. The
direction of the methylation difference (hyper- or hypo-)
between tumor and non-tumor tissues for targeted bis-seq
was 100% concordant with that from 27K and 450K data
[8, 9]. Additional file 1: Figure S2 shows two examples of
mean DNA methylation comparisons for GRASP and
TSPYL5 by targeted bis-seq and 450K array approaches.
Statistically significant DNA hypermethylation was ob-
served in HCC tumor tissue compared to non-tumor tis-
sue for both genes. These data demonstrated the accuracy
and reliability of both targeted bis-seq and Illumina 27K/
450K methylation arrays.
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and normal liver tissues
With more and more epigenomic and genomic studies
completed in tumor tissues, large panels of candidate genes
are available that need further verification for their bio-
logical functions before they can be applied to population-
based molecular epidemiological studies. Comparison of
mRNA expression patterns is an effective way to identify
relevant functional changes and focus on crucial methyla-
tion markers involved in tumorigenesis.
A total of 15 candidate genes (CDKL2, CLCN1, DUOX1,
MAST1, NKX6-2, OTX1, SPAG6, SPDYA, TRIL, USP44,
ZNF397OS, GRASP, TSPYL5, KCNQ2, and PTPRN2) and
three known TSGs (APC, CDKN2A and RASSF1) with
available mRNA expression data in the Oncomine database
(Additional file 1: Table S3) were evaluated for their
biological functions in HCC tumor (n = 418), precursor
(n = 142), and normal liver tissues (n = 325). Another five
genes (ILDR2, SERHL, FAM66B, PROKR2, and REXO1L2P)
were omitted from the analysis of mRNA expression due to
the lack of Oncomine data. As expected, the expression
levels of APC and CDKN2A were significantly down-
regulated in HCC tumor tissues compared to both precur-
sor and normal liver tissues (Additional file 1: Table S4)
[29–32]. Overall, four candidate genes (CLCN1, DUOX1,
GRASP and TSPYL5) were significantly under-expressed in
HCC tumors in comparison with precursor and normal
liver tissues [29–32], but inconsistent non-significant
differences were also observed for CLCN1 and DUOX1
expression between HCC and precursor [29, 30, 33]. The
expression levels of GRASP and TSPYL5 in HCC tumor
tissues were, respectively, 1.828 and −0.148, which were sig-
nificantly lower (Fig. 1) than those in both precursor (2.210
and 1.585) and normal liver tissue (2.134 and 1.527) [29].Fig. 1 Comparisons of mRNA expression for GRASP and TSPYL5 in HCC tum
represents the mRNA expression levels for GRASP (a) and TSPYL5 (b) in HCC
under-expression was observed in HCC tumor tissues for GRASP and TSPYL5
extracted from public Oncomine databasesBecause DNA methylation changes between HCC tumor
and non-tumor tissues did not achieve statistical significance
for DUOX1 (Table 1), down-regulation of its mRNA in
tumor tissue was unlikely due to DNA methylation changes
and was thus excluded from further analysis. Hypermethy-
lated ZNF397OS was only significantly down-regulated in
HCC tumor compared to precursor tissues [32], but not
compared to normal liver tissue. Similarly, hypomethylated
KCNQ2 displayed significant over-expression in tumor com-
pared to precursor tissue [30]. Another four hypermethy-
lated genes (CDKL2, MAST1, SPAG6 and TRIL) exhibited
significant under-expression in tumor compared to normal
liver tissue [29–33], but not precursor tissues. Hypomethy-
lated PTPRN2 was significantly over-expressed in tumor
tissue compared to normal liver tissue (Additional file 1:
Table S4) [30]. The heterogeneous expression patterns of
these genes in HCC tumor vs. precursor and normal liver
tissues need further clarification. Four hypermethylated
genes (NKX6-2, OTX1, SPDYA and USP44) did not show
any significant difference in mRNA expression among
tissues [29, 32], suggesting a minor biological role in hepato-
carcinogenesis, and were excluded from further analysis.
The lack of expression data on five genes (ILDR2, SERHL,
FAM66B, PROKR2, and REXO1L2P) in HCC tissues may
lead us to miss some important candidate genes; but it is
unlikely to impact the functional genes identified in the
current study.
Integrative analyses of CNVs and miRNAs
Integrative analyses of relevant genetic and epigenetic
changes may help us to further understand important
regulators and potential mechanisms associated with the
biological functions of the genes that we have identified.
Gains or losses of copy numbers in DNA have beenor, precursor and normal liver tissues. Log2 median-centered ratio
tumor, precursor and normal liver tissues. Statistically significant
compared to both precursor and normal liver tissues. The data were
Fig. 2 DNA methylation comparisons for HCC tumors with or without
DNA copy number losses in Chr6q region. Chr6q− indicates DNA copy
number losses in this region, NT indicates non-tumor tissue. Two genes
(RGS17 and NR2E1) showed significantly decreased DNA methylation in
HCC tumor tissues with DNA copy number losses in region Chr6q
compared with tissues with no copy number losses
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mRNAs (up- or down-regulation) [48] and play a similar
biological role as DNA hypo- or hyper-methylation.
Integrative analyses of CNVs was performed in HCC tumor
(n = 209), precursor (n = 94) and normal liver tissues
(n = 145) based on the Oncomine database (Additional file
1: Table S3), as well as in our 66 paired HCC tissues. We
found no significant CNV losses for CLCN1, GRASP and
TSPYL5, genes that displayed significant under-expression
in HCC tumor compared to both precursor and normal
liver tissues (Additional file 1: Figure S3). Similarly, no
significant CNV losses were observed for MAST1, SPAG6
and TRIL, genes that showed under-expression in HCC
tissue compared to normal liver tissue (data not shown).
Integrating data on copy number losses and DNA methy-





GRASP hsa-miR-320b −8.97, 0.75








* Bonferroni correction for multiple testingtwo CpG sites in RGS17 (cg16924337) and NR2E1
(cg17386213) that had significantly reduced DNA methyla-
tion in tumors with loss of DNA copy number compared to
those without (Fig. 2). DNA methylation levels in tumor and
non-tumor tissues were, respectively 0.54 and 0.41 for
RGS17 (p= 0.02), and 0.53 and 0.43 for NR2E1 (p= 0.05),
suggesting a potential regulatory role for copy number losses
in liver tumorigenesis in addition to DNA methylation alter-
ation. Therefore, one allele either undergoing DNA hyper-
methylation or loss of copy number may lead to the partial
inactivation of genes with tumor suppressive activity.
Aberrant expression of miRNAs may also regulate func-
tion of the relevant target genes. Among the six hyper-
methylated and under-expressed genes (CLCN1, GRASP,
MAST1, SPAG6, TRIL and TSPYL5) without losses of copy
number, we further examined whether miRNAs that target
those genes are over-expressed in HCC tumor tissue. The
numbers of miRNAs targeting each gene varied from 4 to
51 and included 1-27 detectable miRNAs in liver tissue
(Additional file 1: Table S5). Overall, no significant up-
regulated miRNA was observed in HCC tumor tissue com-
pared to non-tumor tissue. The expression of miR-888
targeting SPAG6 did not show a significant difference (Log2
fold change = 0.11, p = 0.867). In contrast, we found 1-8
significantly under-expressed miRNAs (log2 fold changes
ranging from −0.68 folds to −2.66 folds) in HCC tumors
(Additional file 1: Table S6), suggesting those miRNAs were
unlikely to cause the under-expression of the relevant target
genes (CLCN1, GRASP, MAST1, TRIL and TSPYL5). These
integrative analyses indicate that no significant CNV losses
and over-expressed miRNAs that target GRASP and TSPYL5
were observed in HCC (Table 2), suggesting a minor func-
tional impact of CNVs and miRNAs for these two genes.
Validation of mRNAs expression for GRASP and TSPYL5
The two promising genes (GRASP and TSPYL5) were
further validated in terms of their mRNA expression in the




HCC tumorMean (Log2), SD
−10.10, 0.96 8.95E-03 Down
−9.53, 0.88 7.58E-03 Down
−4.11, 0.55 2.32E-02 Down
−7.35, 0.86 1.42E-02 Down
−4.78, 0.63 3.86E-02 Down
−8.62, 1.08 2.24E-04 Down
−5.89, 1.18 8.94E-03 Down
−10.10, 0.96 8.95E-03 Down
−6.48, 0.70 2.84E-02 Down
Table 3 Log2 expression levels of two candidate mRNAs in
discovery (24 pairs) and validation (42 pairs) sets by qRT-PCR
assays





GRASP 24 pairs −7.21 (1.30) −6.51 (0.89) −1.62 2.75E-02
42 pairs −7.49 (1.41) −6.52 (1.26) −1.96 1.53E-03
TSPYL5 24 pairs −9.67 (1.61) −8.79 (1.13) −1.85 3.68E-02
42 pairs −9.71 (1.63) −8.94 (1.22) −1.71 1.25E-02
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and TSPYL5 were selected based on their consistent DNA
methylation and expression patterns in tumor, precursor
and normal tissues, as well as no significant influence of
CNVs and miRNAs on their functions. The distribution of
GRASP and TSPYL5 expression levels for each sample are
shown in Additional file 1: Figure S4. A consistent and sta-
tistically significant under-expression pattern was observed
for GRASP and TSPYL5 in both the 24 and 42 paired
tumor tissues (Table 3). The fold-changes for GRASP and
TSPYL5 were, respectively −1.62 and −1.85 in the 24 pairs,
and −1.96 and −1.71 in the 42 pairs, which is consistent
with the Oncomine data (Additional file 1: Table S4). When
analyzing correlation of DNA methylation and expression,
we found consistent hypermethylation and repression pat-
tern for GRASP (71% of samples) and TSPYL5 (67%) in the
24 pairs (Additional file 1: Figure S5). In the additional 42
paired HCC tumor and adjacent non-tumor tissues, similar
proportions of tumor tissues with a hypermethylation and
under-expression pattern were observed for GRASP (68%)
and TSPYL5 (78%). The correlation coefficients of DNA
methylation and expression were −0.394 for GRASP
(p = 0.007) and -0.415 for TSPYL5 (p = 0.004), indicating a
major regulatory role for DNA methylation (Table 4). TheTable 4 Integrative analyses for DNA methylation, mRNA expression
Variables
DNA hypermethylation, No (%)
mRNA under-expression, No (%)
Expression difference, Mean (SD)
Methylation difference, Mean (SD)
Copy number loss, No (%)
Copy number gain, No (%)
mRNA over-expression, No (%)
Expression difference, Mean (SD)
Methylation difference, Mean (SD)
Copy number gain, No (%)
Copy number loss, No (%)
* Correlation coefficient = −0.394, p = 0.007; ** Correlation coefficient = −0.415, p = 0
coefficient = −0.032, p = 0.906; ‡ p = 0.031repression of GRASP and TSPYL5 observed in tumor tissue
is more likely through the mechanism of altered DNA
methylation.
Integrative analyses with ENCODE data
To perform integrative analyses of DNA methylation and
the ENCODE data for GRASP and TSPYL5 in HepG2 and
seven other cancer cell lines, we examined the co-operative
role of histone modifications and deoxyribonuclease
(DNase I) hypersensitivity on chromatin activity. Around
the GRASP amplicon located in the promoter region, no
DNase I hypersensitivity peak was observed in HepG2 cells,
indicating inactive chromatin (Fig. 3a). Further investigation
of the GRASP promoter area showed that the active histone
marks (H3K4me1 and H3K27ac) had no signature of up-
regulation in HepG2, but H3K27me3, a repressor, displayed
an increase which is consistent with the status of DNA
hypermethylation in HCC tumor tissue. Similarly, neither
DNase I hypersensitive sites, nor activation of histone
marks (H3K4me1, H3K4me3 and H3K27ac) were observed
around the TSPYL5 amplicon in HepG2 cells (Fig. 3b). No
increase of H3K27me3 was observed around TSPLY5 in
HepG2 cells. The different histone modifications in HepG2
and the other cell lines indicate a potentially specific role
for GRASP and TSPYL5 in hepatocarcinogenesis.
GRASP is located at chromosome 12q13.13 and encodes
a 395 amino acid protein. Identified as an all-trans retinoic
acid-induced gene [49], GRASP interacts with numerous
neuronal proteins of cytohesin family members Grp1 and
ADP-ribosylation factor (Art) [49] to play a role in the
intracellular trafficking of receptors [50–52]. GRASP has
been found to be significantly hypermethylated in HBV-
infected HCC tumor tissue, but changes in expression
were unknown [5]. Recently, GRASP was found to be
significantly hypermethylated in colorectal cancer and also
negatively correlated with expression levels [53]. Theand CNVs in HCC tumor tissues
GRASP TSPYL5
65 (98.5) 64 (97.0)
45 (69.2) 47 (73.4)
−1.63 (1.44)* −1.67 (1.51)**
0.55 (0.13)* 0.36 (0.11)**
4 (8.9)† 1 (2.1)†
14 (31.1) 33 (70.2)
20 (30.8) 17 (26.6)
0.93 (0.79)# 1.12 (1.38)¶
0.44 (0.30)# 0.39 (0.07)¶
7 (35.0)‡ 12 (70.6)‡
4 (30.0) 0 (0.0)
.004; † p = 0.153; # Correlation coefficient = −0.199, p = 0.387; ¶ Correlation
Fig. 3 UCSC genome browser tracks showing histone modifications (H3K4me1, H3K4me3, H3K27me3 and H3K27ac) and DNase I cleavage states around
GRASP (a) and TSPYL5 (b) amplicons in HCC HepG2 and seven other cancer cell lines. Shown from top to bottom is the CpG island; layered H3K4Me1
activating mark, H3K4Me3 promoter specific mark in seven other cancer cell lines; H3K4Me3, H3K27me3, H3K4Me1, H3K27Ac activator marks and DNase I
hypersensitive sites in HCC HepG2 cells; H3K27Ac activator in 7 other cancer cell lines; and GC percent. a: The genome browser map shows the genomic
region around the GRASP (chr12:52,399,000-52,407,500). The bisulfite sequencing data covers 25 CpGs located within the promoter specific the 138th CpG
island as shown. Around the GRASP amplicon, no DNase I hypersensitivity peak was observed in HepG2 cells. Histone marks (H3K4me1 and H3K27ac)
displayed no signature of active regulation in HepG2 cells, while a silencer of H3K27me3 showed a small hill. Unexpectedly, active histone H3K4me3 also
exhibited a peak. The histone modifications for the seven other cancer cell lines displayed high peaks for H3K4me1, H3K4me3 and H3K27ac. b: The genome
browser map shows the genomic region around TSPYL5 (chr8:98,287,500-98,292,500). The bisulfite sequencing data covers 57 CpGs located within the
promoter specific the 100th CpG island as shown. Consistent with DNA hypermethylation and under-expression of mRNA, there were no active histone marks
(H3K4me1, H3K4me3 and H3K27ac), as well as closed chromatin (no peak for DNase I hypersensitive sites) around the TSPYL5 amplicon in HepG2 cells, which
is different from the pattern observed in seven other cancer cell lines (showing high peaks for H3K4me1, H3K4me3 and H3K27ac marks). Unexpected, no
activation of H3K27me3 was observed around TSPLY5 in HepG2 cells
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colorectal tissue and WBC DNA from healthy subjects,
indicating potential usefulness as a non-invasive epigenetic
markers [54]. It is known that CDKN2AINK4a (a tumor
suppressor gene) encodes p14ARF that acts as a checkpoint
within the ARF-MDM2-p53 pathway to activate and
stabilize p53 [55]. When a mutagenic event occurs, the
expression of p14ARF can interrupt the abnormal cellproliferation [56], while the function of GRASP is to
promote ARF-Rac signaling [57]. It is biologically plausible
that methylation alterations in either CDKN2AINK4a or
GRASP may cause dysfunction of this pathway, and initiate
tumorigenesis.
TSPYL5 is a member of the testis-specific protein Y-
encoded-like (TSPY-L) family of genes located on chromo-
some 8q22 and is a target of epigenetic silencing in gliomas
Shen et al. BMC Medical Genomics  (2015) 8:28 Page 9 of 12including glioblastoma [58, 59] and gastric cancers [60].
Upon treatment with the demethylating agent 5-aza-dC in
glioma [58] and gastric cancer [59] cell lines, TSPYL5
expression was restored, indicating epigenetic regulation.
Stable transfection of TSPYL5 in glioma or colon cancer
cell lines inhibited growth [58, 60]. TSPYL5 is frequently
amplified in breast cancer, and displays an oncogene-like
activity. The highest level of expression was found in basal-
like breast cancers that correlated with shortened distant
metastasis-free survival [61]. TSPYL5 can override
senescence-like proliferation arrest and oncogene-induced
senescence and contribute to cell transformation suggesting
its role as a negative regulator of p53 function [61]. TSPYL5
protein was shown to interact with USP7 (a known deubi-
quitylating enzyme for p53), and suppress deubiquitination
of p53 therefore marking it for degradation [61]. Moreover,
the binding of TSPYL5 to USP7 can also effect other
proteins targeted by USP7 for deubiquitylation including
proteins involved in tumor necrosis factor alpha (TNF-α)
induced apoptosis [62]. We observed decreased TSPYL5
levels which would lead to an increase in p53 protein levels.
In normal cells, the p53 protein is low due to rapid degrad-
ation by the proteasome through MDM2 targeted ubiquiti-
nation. Protein levels of p53 have been shown to be higher
in HCC relative to adjacent normal tissue [63] but in
general p53 levels were variable among HCC samples [64].
Thus, TSPYL5 hypermethylation could be a contributing
factor to higher p53 protein levels in some HCC via its
interaction with USP7. More studies are needed to
determine the biological function of low TSPYL5 in HCC.
This integrative analyses and filtering for biologically im-
portant genes regulated by altered methylation is an im-
portant first step in the identification of biomarkers for
epidemiologic studies. The novel findings of the current
study are that the significant repression of GRASP and
TSPYL5 in HCC tumors is likely due to epigenetic regula-
tion, while RGS17 and NR2E1 are functionally regulated by
both DNA methylation and copy number losses. More im-
portantly, many genes with aberrant DNA methylation
were excluded from further evaluation because of lack of
consistent evidence for their biological functions. Therefore,
integrative analysis of available genetic and epigenetic data
provides a high through-put and cost-effective tool to
transform findings from the current study into the next
step of population based epidemiological studies using
non-invasive blood as a surrogate for target tissue. Integra-
tive analysis also makes it feasible to robustly examine the
tissue specificity and interpret results when evaluating the
identified functional biomarkers in epidemiological studies.
Because the ENCODE data does not include HCC cell lines
(SNU-449, JHH2), we performed the integrative analyses
on HepG2 cells derived from a human hepatoblastoma.
The co-operation between DNA methylation and histone
modifications on chromatin activity may be different forthe different types of cell lines, and the results should be
interpreted with caution.
Conclusions
The integrative analyses of epigenomic and genomic
profiles provide us with an effective tool to filter bio-
logically functional epigenetic markers for future epi-
demiological studies. For the first time, the expression
of GRASP and TSPYL5 were identified mainly regulated
by DNA methylation, while RGS17 and NR2E1 genes
may be repressed by the alternative mechanisms of
DNA loss of copy number or hypermethylation. With
multiple layers of –omics data available (exposomics,
metabolomics, phenomics, proteomics, and transcripto-
mics et al.), this approach will become more efficient
and accurate to help epidemiologists distinguish crucial
genes, pathways, epigenetic alterations and environmen-
tal factors that indicate cancer risks, development or
prognosis. In addition, these biologically functional
markers can also be used as preventive or therapeutic
targets that enhance the efficacy of cancer control at the
population level, as well as in personalized medicine by
applying a molecular epidemiological study design inte-
grated with –omics data.
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Additional file 1: Laboratory methods. To display details of methods
for DNA extraction; the Infinium Methylation 27K/450K assays; TaqMan
Low Density Arrays; qRT-PCR and targeted bis-seq. Figure S1. DNA
methylation results of targeted bis-seq for GRASP (covering 25 CpG sites)
and TSPYL5 (covering 57 CpG sites). The heatmaps for GRASP and TSPYL5
contain data for 23 paired non-tumor/tumor samples. One paired sample
did not have data for the non-tumor so the data was removed. The non-
tumor samples are grouped at the top and the corresponding tumor
samples are at the bottom. The far left columns contain the class (non-
tumor (N) or tumor (T) and then the patient number. The next columns
show the percent methylation for each of CpG site covered and colored
according to the chart. The column to the far right contains an average
percent methylation for all the CpGs covered for that sample. Overall,
within each sample, DNA methylation levels across different CpG sites
were consistent no matter tumor tissue status. Most tumor tissues
displayed higher levels of DNA methylation compared to relevant
adjacent non-tumor tissues for individual CpG site and the mean of all
CpG sites. Figure S2. DNA methylation comparisons for GRASP and
TSPYL5 by targeted bis-seq and 450K approaches. Box-plot diagrams were
analyzed to compare the quantities of methylation differences using two
different approaches. The two examples of DNA methylation
Shen et al. BMC Medical Genomics  (2015) 8:28 Page 10 of 12comparisons for GRASP and TSPYL5 indicate that statistically significant
DNA hypermethylation was observed in HCC tumor tissue compared to
non-tumor tissue. Figure S3. Gains and losses of CNV in HCC tumor,
precursor and normal liver tissues for six representative genes based on
the Oncomine database. Box-plot diagrams were analyzed to compare
hypermethylated genes (CLCN1, GRASP and TSPYL5) under-expressed in
HCC tumor tissue, and that display no significant losses of CNV
compared to precursor and normal liver tissues. In contrast, statistically
significant CNV losses were found in HCC tumor tissue for
hypermethylated CDKL2 and ZNF397OS, and significant CNV gains were
observed for hypomethylated KCNQ2 and PTPRN2, suggesting potential
important role of CNVs in regulation these genes’ function. Figure S4.
Distribution of GRASP and TSPYL5 expression levels for each sample in 24
pairs and 42 pairs of HCC tissues. A consistent and statistically significant
under-expression pattern was observed in HCC tumor tissues for GRASP
and TSPYL5 in both the 24 and 42 paired samples. Figure S5. DNA
methylation changes and relevant genes’ (GRASP, TSPYL5) expression (Log
2 fold change) pattern in discovery (24 pairs) and validation (42 pairs)
sets. DNA methylation changes (hyper-, hypo-) and relevant genes’
expression (under-, over-) between individual tumor and adjacent non-
tumor tissues were analyzed. There were, respectively 65 and 64 HCC
tumor tissues that showed significant DNA hypermethylation for GRASP
and TSPYL5. Highly consistent hypermethylation and repression patterns
were observed in tumor tissues for GRASP (17/24, 71%) and TSPYL5 (16/
24, 67%) in the training set (Figure S5A). Validation in an additional
testing set (Figure S5B) found a similar proportion of tumor tissues with
hypermethylation and under-expression pattern for GRASP (28/41, 68%)
and TSPYL5 (31/40, 78%). However, less than one third of the tumor
tissues showed a heterogeneous pattern of DNA hypermethylation and
mRNA over-expression (31% and 27% for GRASP and TSPYL5, respectively),
indicating other potential mechanisms may be involved in the regulation
of expression. Table S1. Genomic locations of candidate genes and
covered CpG sites of amplicons for targeted bis-seq approach. Table S2.
The clinical and pathological characteristics of 24 HCC patients in the
current study. Table S3. Oncomine databases for integrative gene
expression and copy number variations (CNVs) analyses in liver tissues.
Table S4. Representative Oncomine mRNAs expression data (Log2) to
display concordant patterns with DNA methylation alterations. Table S5.
Types of miRNAs that target six hypermethylated genes without losses of
CNVs. Table S6. Comparison of significant expressed miRNAs that target
six hypermethylated genes without losses of CNVs. Table S7.
Frequencies of copy number loss in HCC tumor by methylation status.
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